Procyon Corporation (PCYN) Fair Value & Analysis

Healthcare · US · Market cap $1.6M

A solid business, but screening 75% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case ($0.0900). The favourable scenario is already priced in.
• Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.

How to read this chart

60‑month range $0.0013 – $0.9500 · fair‑value band $0.0500 – $0.0900 · the $0.2800 price screens above the $0.0700 fair value. Dashed = 300-day average. As of Jul 19, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Procyon Corporation (PCYN) currently trades at $0.2800, while our model-based Fair Value estimate is $0.0700, implying the stock looks roughly 75.0% overvalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Procyon Corporation generated revenue of $5.0M at a net margin of -6.8%. Revenue grew 17.5% year over year. It earns a return on equity of -13.9%. Fundamentals as of Jul 19, 2026

Our scenario range runs from $0.0500 (bear case) to $0.0900 (bull case); at $0.2800, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 180% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -75%, PCYN screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models ($0.3700) versus Dividend Discount ($0.0200). Highest evidence: Residual Income (76).

Key figures & financial health

Quality Score breakdown

About the company

Procyon Corporation, together with its subsidiaries, manufactures and markets wound and skin care products primarily in the United States.

Full company description

Procyon Corporation, together with its subsidiaries, manufactures and markets wound and skin care products primarily in the United States. It provides AMERIGEL, an advanced skin and wound care products, including hydrogel wound dressing, post op surgical kits, saline wound washes, and care and barrier lotions; HELIX3 Bioactive Collagen products, such as collagen powder, gel, and matrix; and calcium alginate dressing, foam dressing, amerx gauze dressing, hyrdocolloid dressing, as well as wound care kits, including calcium alginate, collagen matrix, collagen powder, foam, hydrogel, and rolled gauze wound care kits under the AMERX brand. The company also offers AMERIGEL hand sanitizer; EXTREMIT-EASE compression garment products; Advantagen, a surgical collagen powder that promotes wound closure and reduces the potential for surgical site infection; calcium alginate, foam, and gauze dressings; retention tapes; and helix collagen gel. It sells its products to institutional customers such as hospitals, wound care clinics, skilled nursing facilities, home health agencies, physicians, and other health care practitioners; and retail customers through distributors, and direct and internet sales, as well as through independent and retail chain drug stores. Procyon Corporation was incorporated in 1987 and is based in Oldsmar, Florida.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Procyon Corporation reported revenue of $6.7M in FY2025 versus $4.7M in FY2021, a compound +9.0%/yr. Reported net income was $33.9K in FY2025, compounding −53.0%/yr from FY2021.

PCYN screens 75% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 622 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.